Korean biopharmaceutical companies are exchanging joy and sorrow over out-licensing agreements. Last month, three companies, including HK inno.N, have successfully signed agreements to out-licensing of their new drug candidates in addition to AprilBio and ISU Abxis.

In contrast, there are instances where new drug candidates that have been successfully out-licensing are later returned.

GC Cell announced that a collaborative R&D agreement with Artiva Biotherapeutic, its U.S. subsidiary, for three treatments for CAR-NK solid tumors in 2021 has terminated.

Furthermore, Olix Pharmaceuticals and Curacle received notifications of contract terminations from France’s Thea Open Inn